Primerica, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing. Primerica serves middle-income households in the U.S. and Canada through independent representatives, underwriting term life insurance and distributing investment, savings, and other third-party products.
Financial performance and key metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Total revenue | $2.218 billion | $2.053 billion | +8% |
| Net premiums | $1.326 billion | $1.184 billion | +12% |
| Commissions and fees | $751.3 million | $713.8 million | +5% |
| Net investment income | $83.8 million | $94.1 million | −11% |
| Income before taxes | $506.7 million | $477.1 million | +6% |
| Net income | $386.2 million | $366.4 million | +5% |
| Diluted earnings per share | $9.57 | $8.62 | +11% |
| Operating cash flow | $643.4 million | $485.5 million | +33% |
Net margin was approximately 17.4%, compared with 17.9% in 2019. Benefits and claims rose 25% to $615.6 million, principally reflecting elevated COVID-19 mortality and growth in the insured book. Lower policy lapses reduced deferred acquisition cost amortization by approximately $53 million, partly offsetting higher claims.
- Term life: Policies issued rose to 352,868 from 287,809; face amount issued increased to $109.4 billion from $94.0 billion. Face amount in force reached $858.8 billion, up 6%.
- Investment and savings: Product sales increased 4% to $7.843 billion. Ending client account assets were $81.5 billion, up from $70.5 billion; net inflows were $2.3 billion.
- Balance sheet and liquidity: Cash and cash equivalents were $547.6 million; total assets were $14.91 billion and stockholders’ equity was $1.84 billion. Management said operating cash flows were expected to support liquidity over the next 12 months.
- Debt and capital: $375 million of 4.75% senior notes mature July 2022. The $200 million revolving facility was undrawn at year-end. A $1.346 billion surplus note associated with reserve financing is paired with a held-to-maturity note asset; the arrangement is described as non-recourse to the Parent Company and Primerica Life. U.S. insurance subsidiaries were above regulatory capital requirements, and the Canadian subsidiary was in compliance.
- Shareholder returns: FY2020 dividends declared were $1.60 per share; share repurchases totaled $231.4 million. The Board declared a $0.47 quarterly dividend in Q1 2021 and authorized a new repurchase program of up to $300 million.
Material changes and management commentary
- COVID-19 restrictions shifted client and recruiting meetings to remote tools and disrupted licensing classes and examination access. New recruits rose 42% to 400,345; year-end life-licensed representatives rose to 134,907, including temporary and extended licenses related to the pandemic.
- COVID-related claims increased mortality costs; management reported claims were approximately $33 million above historical trends. Strong policy persistency and protection-product demand also supported premium growth and reduced lapses.
- Investment markets recovered after a sharp first-quarter decline. Year-end client account assets benefited from market appreciation, higher inflows, and lower redemptions. Lower annuity demand reflected less attractive provider benefits amid low interest rates.
- Investment income declined due to lower portfolio yields and weaker returns on the deposit asset supporting a 10% coinsurance agreement. Realized investment losses were $5.0 million, including credit losses on issuers in distressed sectors and lower equity-security values.
- Management provided no specific earnings or revenue guidance. It expects COVID-19, mortality, persistency, licensing, and market effects to remain uncertain. The company planned to expand its mortgage program in 2021; its biennial convention was rescheduled from 2021 to summer 2022.
Risks, contingencies, and unusual items
- Key exposures include pandemic-related mortality and persistency changes, reinsurance counterparty performance, investment credit and interest-rate risk, and dependence on third-party product providers.
- Regulatory changes may affect representative classification, standards of conduct, licensing, and compensation. Canada’s deferred sales charge ban is scheduled to take effect June 1, 2022 in participating provinces; the company had not quantified its impact.
- Two reinsurers associated with runoff blocks were in receivership; the company recognized an allowance for expected credit losses. Total reinsurance recoverables were $4.274 billion, with an allowance of $7.1 million.
- The $375 million senior notes mature in 2022. The company reported compliance with debt covenants and no short-term borrowings. The filing identifies ongoing ordinary-course disputes and regulatory inquiries, but states no pending legal proceeding required disclosure under Item 3; certain potential losses could not be estimated.
- Auditors issued unqualified opinions on the financial statements and internal control. The estimate of term-life future policy benefits, a $6.791 billion liability, was identified as a critical audit matter because of uncertainty in mortality, persistency, and disability assumptions.
Important facts for investors to verify
- Track COVID-related claims and whether persistency and new policy sales normalize; assess resulting claims expense, reserves, and acquisition-cost amortization.
- Review reinsurance recoverables, counterparties, collateral, and the effect of any deterioration or recapture of ceded business.
- Monitor the 2022 senior-note maturity, subsidiary dividend capacity, and Parent Company liquidity and capital-return plans.
- Assess the effects of Canadian compensation-rule changes and evolving U.S. and Canadian standards-of-conduct requirements.
- Evaluate sensitivity to interest rates, credit quality, and market values, including the reported $105.6 million estimated fixed-income portfolio decline under a 100-basis-point rate increase.